# DA Katz Announces Padlocking of Illegal Cannabis Storefront in Laurelton > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/illegal-cannabis-storefront-enforcement-laurelton/ > **Published:** 2026-03-27T01:02:17-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:37:02-04:00 > **Clinical Summary:** DA Katz announces illegal cannabis storefront enforcement in Laurelton, highlighting patient safety and regulatory challenges in unlicensed cannabis sales. --- ✦ New CED Clinical Relevance  #70Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News  |  CED Clinic Patient SafetyProduct QualityRegulationCannabis AccessPublic Health Why This Matters Enforcement against unlicensed cannabis retailers directly impacts patient safety, as unregulated products lack quality control, testing, and dosing standards essential for [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/) patients. This enforcement action highlights the ongoing challenge patients face in accessing safe, regulated cannabis products while illegal storefronts continue to operate. Clinical Summary Queens District Attorney Melinda Katz announced the closure of an unlicensed cannabis retail operation in Laurelton through civil enforcement action. This represents continued efforts by law enforcement to address illegal cannabis sales in New York, where licensed dispensaries operate alongside numerous unlicensed retailers. The action reflects broader regulatory challenges as states implement legal cannabis frameworks while unlicensed operators continue to serve consumers with untested products. Dr. Caplan’s Take “I consistently advise patients to source cannabis only from licensed dispensaries where products undergo mandatory testing for contaminants and accurate labeling. These enforcement actions, while necessary for public safety, underscore why patients need clearer guidance on identifying legitimate sources.” Clinical Perspective 🧠 Clinicians should counsel patients that unlicensed cannabis products carry significant safety risks including contamination, inaccurate potency labeling, and unknown additives. Patients should verify dispensary licensing status through state regulatory websites and understand that ‘medical-looking’ packaging does not guarantee product safety or regulatory compliance. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20DA%20KATZ%20ANNOUNCES%20PADLOCKING%20OF%20ILLEGAL%20CANNABIS%20STOREFRONT%20IN%20LAURELTON%20%40drcaplan&url=https%3A//queensda.org/da-katz-announces-padlocking-of-illegal-cannabis-storefront-in-laurelton/)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//queensda.org/da-katz-announces-padlocking-of-illegal-cannabis-storefront-in-laurelton/)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20DA%20KATZ%20ANNOUNCES%20PADLOCKING%20OF%20ILLEGAL%20CANNABIS%20STOREFRONT%20IN%20LAURELTON%20--%20via%20%40drcaplan.bsky.social%20https%3A//queensda.org/da-katz-announces-padlocking-of-illegal-cannabis-storefront-in-laurelton/)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://queensda.org/da-katz-announces-padlocking-of-illegal-cannabis-storefront-in-laurelton/](https://queensda.org/da-katz-announces-padlocking-of-illegal-cannabis-storefront-in-laurelton/) Table of Contents - [FAQ](#FAQ)[What is the clinical relevance rating of this cannabis news?](#What_is_the_clinical_relevance_rating_of_this_cannabis_news) - [What are the main areas of concern highlighted in this cannabis update?](#What_are_the_main_areas_of_concern_highlighted_in_this_cannabis_update) - [Why is this classified as having “notable clinical interest”?](#Why_is_this_classified_as_having_8220notable_clinical_interest8221) - [What type of healthcare professionals should pay attention to this update?](#What_type_of_healthcare_professionals_should_pay_attention_to_this_update) - [How does this relate to current cannabis regulation and patient care?](#How_does_this_relate_to_current_cannabis_regulation_and_patient_care) - [Related](#Related) ## FAQ #### What is the clinical relevance rating of this cannabis news? This article has been assigned CED Clinical Relevance #70, indicating “Notable Clinical Interest.” This rating signifies emerging findings or policy developments that are worth monitoring closely by healthcare professionals. #### What are the main areas of concern highlighted in this cannabis update? The key focus areas include patient safety, product quality, regulation, and cannabis access. These categories represent critical aspects of [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/) that impact clinical practice and [patient care](https://cedclinic.com/cannabis-cardiovascular-risk-impact/). #### Why is this classified as having “notable clinical interest”? The classification suggests this contains emerging findings or policy developments in the cannabis field. Healthcare providers should monitor these developments as they may influence treatment decisions or regulatory compliance. #### What type of healthcare professionals should pay attention to this update? This update is relevant for clinicians working in [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/), particularly those at CED Clinic. Any healthcare provider prescribing or considering medical cannabis for patients should be aware of these developments. #### How does this relate to current cannabis regulation and patient care? The focus on regulation, product quality, and patient safety indicates this update addresses current challenges in medical cannabis practice. It likely provides guidance for ensuring safe and effective [cannabis-based treatments](https://cedclinic.com/cannabis-medical-clinic-experience-beyond-smoking-vaping/) within regulatory frameworks. {“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “DA KATZ ANNOUNCES PADLOCKING OF ILLEGAL CANNABIS STOREFRONT IN LAURELTON”, “url”: “https://queensda.org/da-katz-announces-padlocking-of-illegal-cannabis-storefront-in-laurelton/”, “datePublished”: “2026-03-27T01:18:32Z”, “about”: “da katz announces padlocking illegal cannabis”} [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [LA ballot measure wants to tax illegal cannabis shops, but enforcement may be difficult](https://cedclinic.com/cannabis-tax-impact-on-patient-safety-la-ballot-measure/) Explore challenges in taxing illegal cannabis shops and enforcement complexities in Los Angeles. [Read More](https://cedclinic.com/cannabis-tax-impact-on-patient-safety-la-ballot-measure/) [US (MO): State recalls contaminated cannabis products](https://cedclinic.com/us-mo-state-recalls-contaminated-cannabis-products/) Learn about state recalls of contaminated cannabis products and implications for patient safety. [Learn More](https://cedclinic.com/us-mo-state-recalls-contaminated-cannabis-products/) [New Clinical Insights on Cannabis and Patient Outcomes](https://cedclinic.com/new-clinical-insights-on-cannabis-and-patient-outcomes/) Discover recent clinical insights on [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) and its impact on patient health outcomes. [Explore Insights](https://cedclinic.com/new-clinical-insights-on-cannabis-and-patient-outcomes/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).